Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Search results for: 'Cov'

Items 2071 - 2080 of 3026

Show
per page
  • 98.00%

    76.39 kDa (predicted); 112.68 kDa (reducing conditions)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutation T19I, L24S, del25-27, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529 sublineage BA.2). Predicted N terminal: Val 16

    C-His

    100 μg
  • 98.00%

    26.46 kDa (predicted); 33.90 kDa (reducing condition, due to glycosylation)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation R346S, N394S, Y449N, E484K, F490R, N501Y) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.640.2). Predicted N terminal: Arg 319

    C-His

    100 μg
  • 98.00%

    26.56 kDa (predicted); 34.36 kDa (reducing condition, due to glycosylation)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation Q414K, N450K) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.214.2). Predicted N terminal: Arg 319

    C-His

    100 μg
  • 98.00%

    26.46 kDa (predicted); 32.88 kDa (reducing condition, due to glycosylation)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation R346S, N394S, Y449N, F490R, N501Y) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.640). Predicted N terminal: Arg 319

    C-His

    100 μg
  • 98.00%

    138.28 kDa (predicted)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations D614G,F817P, A892P, A899P,A942P, K986P, V987P and furin cleavage site mutants) was expressed with bacteriophage T4 fibritin and a C-terminal polyhistidine tag followed by an AVI tag. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. Predicted N terminal: Val 16

    C-His-Avi

    20 μg
  • 98.00%

    136.30 kDa (predicted)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations T19R, E156G, del157-158, A222V, L452R, T478K, D614G, P681R, D950N,F817P, A892P, A899P,A942P, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant AY.4.2) which emerged in the United Kingdom. Predicted N terminal: Val 16

    C-His

    100 μg
  • 98.00%

    135.71 kDa (predicted)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations G75V, T76I, R246N, SYLTPGD247-253del, L452Q, F490S, D614G, T859N,F817P, A892P, A899P,A942P, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant C.37) which emerged in the Peru. Predicted N terminal: Val 16

    C-His

    100 μg
  • 98.00%

    136.59 kDa (predicted)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F,F817P, A892P, A899P,A942P, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant P.1) which emerged in the Brazil. Predicted N terminal: Val 16

    C-His

    100 μg
  • 98.00%

    136.05 kDa (predicted)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations T19R, E156G, DEL157-158, L452R, T478K, D614G, P681R, D950N,F817P, A892P, A899P,A942P, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.7 +E484K). Predicted N terminal: Val 16

    C-His

    100 μg
  • 98.00%

    136.27 kDa (predicted)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations T19R, E156G, DEL157-158, L452R, T478K, D614G, P681R, D950N,F817P, A892P, A899P,A942P, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant AY.3, AY.3.1) which emerged in the India. Predicted N terminal: Val 16

    C-His

    100 μg

Items 2071 - 2080 of 3026

Show
per page